Vitamin D actions in mammary gland and breast cancer

Vitamin D

Volumn , Issue , 2011, Pages 1657-1673

  Welsh, JoEllen ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881159153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10085-X     Document Type: Chapter

References (149)

1. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010, 220:263-280.
2. Ruder E.H., Dorgan J.F., Kranz S., Kris-Etherton P.M., Hartman T.J. Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin. Breast Cancer 2008, 8:334-342.
3. Eisman J.A., Macintyre I., Martin T.J., Frampton R.J., King R.J. Normal and malignant breast tissue is a target organ for 25-(OH)2 vitamin D3. Clin. Endocrinol. (Oxf.) 1980, 13:267-272.
4. Thorne J., Campbell M.J. The vitamin D receptor in cancer. Proc. Nutr. Soc. 2008, 67:115-127.
5. Welsh J. Vitamin D and prevention of breast cancer. Acta. Pharmacol. Sin. 2007, 28:1373-1382.
6. Wu G., Fan R.S., Li W., Ko T.C., Brattain M.G. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:1555-1563.
7. Simboli-Campbell M., Narvaez C.J., vanWeelden K., Tenniswood M., Welsh J. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat 1997, 42:31-41.
8. James S.Y., Mackay A.G., Colston K.W. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58:395-401.
9. Mork-Hansen C., Binderup L., Hamberg K.J., Carlberg C. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 2001, 6:D820-848.
10. Flanagan L., Packman K., Juba B., O'Neill S., Tenniswood M., Welsh J. Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol. 2003, 84:181-192.
11. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996, 10:142-153.
12. Saramaki A., Banwell C.M., Campbell M.J., Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res. 2006, 34:543-554.
13. Inoue T., Kamiyama J., Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J. Biol. Chem. 1999, 274:32309-32317.
14. Verlinden L., Verstuyf A., Convents R., Marcelis S., Van Camp M., Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell Endocrinol. 1998, 142:57-65.
15. Bettoun D.J., Buck D.W., Lu J., Khalifa B., Chin W.W., Nagpal S. A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J. Biol. Chem. 2002, 277:24847-24850.
16. Lazzaro G., Agadir A., Qing W., Poria M., Mehta R.R., Moriarty R.M., et al. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur. J. Cancer 2000, 36:780-786.
17. Wang Q., Lee D., Sysounthone V., Chandraratna R.A.S., Christakos S., Korah R., et al. 1,25-Dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res. Treat 2001, 67:157-168.
18. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I.P., et al. 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 1995, 55:2822-2830.
19. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75:193-207.
20. James S.Y., Mackay A.G., Colston K.W. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J. Mol. Endocrinol. 1995, 14:391-394.
21. J. Welsh Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol. 72:537-545.
22. Simboli-Campbell M., Narvaez C.J., Tenniswood M., Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 1996, 58:367-376.
23. Valrance M.E., Brunet A.H., Acosta A., Welsh J. Dissociation of growth arrest and CYP24 induction by VDR ligands in mammary tumor cells. J. Cell Biochem. 2007, 101:1505-1519.
24. Pirianov G., Danielsson C., Carlberg C., James S.Y., Colston K.W. Potentiation by vitamin D analogs of TNFalpha and ceramide-induced apoptosis in MCF-7 cells is associated with activation of cytosolic phospholipase A2. Cell Death Differ. 1999, 6:890-901.
25. Nolan E., Donepudi M., VanWeelden K., Flanagan L., Welsh J. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells. Mol. Cell Biochem. 1998, 188:13-20.
26. Chaudhry M., Sundaram S., Gennings C., Carter H., Gewirtz D.A. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother. Pharmacol. 2001, 47:429-436.
27. Sundaram S., Gewirtz D.A. The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation. Radiat. Res. 1999, 152:479-486.
28. Narvaez C.J., Byrne B.M., Romu S., Valrance M., Welsh J. Induction of apoptosis by 1,25-dihydroxyvitamin D(3) in MCF-7 Vitamin D(3)-resistant variant can be sensitized by TPA. J. Steroid Biochem. Mol. Biol. 2003, 84:199-209.
29. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem. 2001, 276:9101-9107.
30. Mathiasen I.S., Lademann U., Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999, 59:4848-4856.
31. Weitsman G.E., Ravid A., Liberman U.A., Koren R. Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann. NY Acad. Sci. 2003, 1010:437-440.
32. Mathiasen I.S., Sergeev I.N., Bastholm L., Elling F., Norman A.W., Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J. Biol. Chem. 2002, 277:30738-30745.
33. Hoyer-Hansen M., Bastholm L., Mathiasen I.S., Elling F., Jaattela M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 2005, 12:1297-1309.
34. Hoyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol. Cell 2007, 25:193-205.
35. Gewirtz D.A., Hilliker M.L., Wilson E.N. Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells. Radiother. Oncol. 2009, 92:323-328.
36. James S.Y., Mackay A.G., Binderup L., Colston K.W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J. Endocrinol. 1994, 141:555-563.
37. Campbell M.J., Gombart A.F., Kwok S.H., Park S., Koeffler H.P. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 2000, 19:5091-5097.
38. Buras R.R., Schumaker L.M., Davoodi F., Brenner R.V., Shabahang M., Nauta R.J., et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res. Treat. 1994, 31:191-202.
39. Abe-Hashimoto J., Kikuchi T., Matsumoto T., Nishii Y., Ogata E., Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 1993, 53:2534-2537.
40. Love-Schimenti C.D., Gibson D.F., Ratnam A.V., Bikle D.D. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer Res. 1996, 56:2789-2794.
41. Stoica A., Saceda M., Fakhro A., Solomon H.B., Fenster B.D., Martin M.B. Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J. Cell Biochem. 1999, 75:640-651.
42. Swami S., Krishnan A.V., Feldman D. 1Alpha,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 2000, 6:3371-3379.
43. Larsen S.S., Heiberg I., Lykkesfeldt A.E. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br. J. Cancer 2001, 84:686-690.
44. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32-42.
45. Rozen F., Yang X.F., Huynh H., Pollak M. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J. Natl. Cancer Inst. 1997, 89:652-656.
46. Rozen F., Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int. J. Oncol. 1999, 15:589-594.
47. Xie S.P., James S.Y., Colston K.W. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J. Endocrinol. 1997, 154:495-504.
48. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 2004, 18:1109-1119.
49. Xie S.P., Pirianov G., Colston K.W. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur. J. Cancer 1999, 35:1717-1723.
50. McGaffin K.R., Chrysogelos S.A. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J. Mol. Endocrinol. 2005, 35:117-133.
51. Matthews D., Laporta E., Zinser G.M., Narvaez C.J., Welsh J. Genomic vitamin D signaling in breast cancer: insights from animal models and human cells. J. Steroid Biochem. Mol. Biol. 2010, 121:362-367.
52. Towsend K., Trevino V., Falciani F., Stewart P.M., Hewison M., Campbell M.J. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 2006, 71:111-123.
53. Lee H.J., Liu H., Goodman C., Ji Y., Maehr H., Uskokovic M., et al. Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem. Pharmacol. 2006, 72:332-343.
54. Swami S., Raghavachari N., Muller U.R., Bao Y.P., Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 2003, 80:49-62.
55. Wu Y., Craig T.A., Lutz W.H., Kumar R. Identification of 1 alpha,25-dihydroxyvitamin D3 response elements in the human transforming growth factor beta 2 gene. Biochemistry 1999, 38:2654-2660.
56. Koli K., Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 1995, 55:1540-1546.
57. Yang L., Yang J., Venkateswarlu S., Ko T., Brattain M.G. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J. Cell Physiol. 2001, 188:383-393.
58. Bizzarri M., Cucina A., Valente M.G., Tagliaferri F., Borrelli V., Stipa F., et al. Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. J. Surg. Res. 2003, 110:332-337.
59. Krishnan A.V., Trump D.L., Johnson C.S., Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 2010, 39:401-418.
60. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65:7917-7925.
61. Mineva N.D., Wang X., Yang S., Ying H., Xiao Z.X., Holick M.F., et al. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J. Cell Physiol. 2009, 220:593-599.
62. Hewison M., Zehnder D., Chakraverty R., Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol. Cell Endocrinol. 2004, 215:31-38.
63. Stein T., Morris J.S., Davies C.R., Weber-Hall S.J., Duffy M.A., Heath V.J., et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 2004, 6:R75-91.
64. Devitt A., Parker K.G., Ogden C.A., Oldreive C., Clay M.F., Melville L.A., et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14-/? mice. J. Cell Biol. 2004, 167:1161-1170.
65. Maruyama R., Aoki F., Toyota M., Sasaki Y., Akashi H., Mita H., et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 2006, 66:4574-4583.
66. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. 2010, 17:273-285.
67. Swami S., Raghavachari N., Muller U.R., Bao Y.P., Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 2003, 80:49-62.
68. Byrne B., Welsh J. Identification of novel mediators of vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J. Steroid Biochem. Mol. Biol. 2007, 103:703-707.
69. Koli K., Keski-Oja J. 1Alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000, 11:221-229.
70. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharmacol. 1990, 178:247-250.
71. Majewski S., Skopinska M., Marczak M., Szmurlo A., Bollag W., Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J. Investig. Dermatol. Symp. Proc. 1996, 1:97-101.
72. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 2000, 87:214-220.
73. Matsumoto H., Iino Y., Koibuchi Y., Andoh T., Horii Y., Takei H., et al. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol. Rep. 1999, 6:349-352.
74. Merke J., Milde P., Lewicka S., Hugel U., Klaus G., Mangelsdorf D.J., et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J. Clin. Invest. 1989, 83:1903-1915.
75. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
76. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009, 69:967-975.
77. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nature Gen. 2000, 25:144-146.
78. Fischer D., Becker S., Cordes T., Bucker B., Diedrich K., Friedrich M., et al. Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res. 2009, 29:3641-3645.
79. Townsend K., Banwell C.M., Guy M., Colston K.W., Mansi J.L., Stewart P.M., et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin. Cancer Res. 2005, 11:3579-3586.
80. Kemmis C.M., Welsh J. Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J. Cell Biochem. 2008, 105:980-988.
81. Cordes T., Diesing D., Becker S., Fischer D., Diedrich K., Friedrich M. Expression of splice variants of 1alpha-hydroxylase in mcf-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 103:326-329.
82. Rowling M.J., Kemmis C.M., Taffany D.A., Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J. Nutr. 2006, 136:2754-2759.
83. Chlon T.M., Taffany D.A., Welsh J., Rowling M.J. Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin D-binding protein in human mammary cells. J. Nutr. 2008, 138:1323-1328.
84. Colston K., Wilkinson J.R., Coombes R.C. 1,25-Dihydroxyvitamin D3 binding in estrogen-responsive rat breast tumor. Endocrinology 1986, 119:397-403.
85. Zinser G.M., McEleney K., Welsh J. Characterization of mammary tumor cell lines from wild type and vitamin D(3) receptor knockout mice. Mol. Cell Endocrinol. 2003, 200:67-80.
86. Escaleira M.T., Sonohara S., Brentani M.M. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 45:257-263.
87. Escaleira M.T., Brentani M.M. Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res. Treat. 1999, 54:123-133.
88. Krishnan A.V., Feldman D. Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors. J. Bone Miner. Res. 1991, 6:1099-1107.
89. Wietzke J.A., Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2003, 84:149-157.
90. Byrne I.M., Flanagan L., Tenniswood M.P., Welsh J. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 2000, 141:2829-2836.
91. Narvaez C.J., Vanweelden K., Byrne I., Welsh J. Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996, 137:400-409.
92. Kommagani R., Payal V., Kadakia M.P. Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J. Biol. Chem. 2007, 282:29847-29854.
93. Kommagani R., Caserta T.M., Kadakia M.P. Identification of vitamin D receptor as a target of p63. Oncogene 2006, 25:3745-3751.
94. Seoane S., Ben I., Centeno V., Perez-Fernandez R. Cellular expression levels of the vitamin D receptor are critical to its transcriptional regulation by the pituitary transcription factor Pit-1. Mol. Endocrinol. 2007, 21:1513-1525.
95. Mittal M.K., Myers J.N., Misra S., Bailey C.K., Chaudhuri G. In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem. Biophys. Res. Commun. 2008, 372:30-34.
96. Agadir A., Lazzaro G., Zheng Y., Zhang X.K., Mehta R. Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 1999, 20:577-582.
97. Banwell C.M., MacCartney D.P., Guy M., Miles A.E., Uskokovic M.R., Mansi J., et al. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin. Cancer Res. 2006, 12:2004-2013.
98. Abedin S.A., Banwell C.M., Colston K.W., Carlberg C., Campbell M.J. Epigenetic corruption of VDR signalling in malignancy. Anticancer Res. 2006, 26:2557-2566.
99. Narvaez C.J., Byrne B.M., Romu S., Valrance M., Welsh J. Induction of apoptosis by 1,25-dihydroxyvitamin D3 in MCF-7 Vitamin D3-resistant variant can be sensitized by TPA. J. Steroid Biochem. Mol. Biol. 2003, 84:199-209.
100. Hansen C.M., Rohde L., Madsen M.W., Hansen D., Colston K.W., Pirianov G., et al. MCF-7/VD(R): a new vitamin D resistant cell line. J. Cell Biochem. 2001, 82:422-436.
101. Narvaez C.J., Welsh J. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology 1997, 138:4690-4698.
102. VanWeelden K., Flanagan L., Binderup L., Tenniswood M., Welsh J. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998, 139:2102-2110.
103. Freake H.C., Abeyasekera G., Iwasaki J., Marcocci C., MacIntyre I., McClelland R.A., et al. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res. 1984, 44:1677-1681.
104. Eisman J.A., Suva L.J., Martin T.J. Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers. Cancer Res. 1986, 46:5406-5408.
105. Berger U., Wilson P., McClelland R.A., Colston K., Haussler M.R., Pike J.W., et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res. 1987, 47:6793-6799.
106. Berger U., McClelland R.A., Wilson P., Greene G.L., Haussler M.R., Pike J.W., et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991, 51:239-244.
107. Friedrich M., Villena-Heinsen C., Tilgen W., Schmidt W., Reichrat J., Axt-Fliedner R. Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res. 2002, 22:1919-1924.
108. Colston K.W., Berger U., Coombes R.C. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:188-191.
109. Sundaram S., Beckman M.J., Bajwa A., Wei J., Smith K.M., Posner G.H., et al. QW-1624F2-2, a synthetic analogue of 1,25-dihydroxyvitamin D3, enhances the response to other deltanoids and suppresses the invasiveness of human metastatic breast tumor cells. Mol. Cancer Ther. 2006, 5:2806-2814.
110. Hussain E.A., Mehta R.R., Ray R., Das Gupta T.K., Mehta R.G. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy. Recent Results Cancer Res. 2003, 164:393-411.
111. Maehr H., Uskokovic M., Adorini L., Penna G., Mariani R., Panina P., et al. Calcitriol derivatives with two different side chains at C-20 III. An epimeric pair of the gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition. J. Steroid Biochem. Mol. Biol. 2007, 103:277-281.
112. Lee H.J., So J.Y., DeCastro A., Smolarek A., Paul S., Maehr H., et al. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J. Steroid Biochem. Mol. Biol. 2010, 121:408-412.
113. Lee H.J., Paul S., Atalla N., Thomas P.E., Lin X., Yang I., et al. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev. Res. (Phila. Pa.) 2008, 1:476-484.
114. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
115. James S.Y., Mercer E., Brady M., Binderup L., Colston K.W. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 1998, 125:953-962.
116. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D., et al. The vitamin D analogue EB1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 2000, 60:4412-4418.
117. Koshizuka K., Koike M., Asou H., Cho S.K., Stephen T., Rude R.K., et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat. 1999, 53:113-120.
118. Koshizuka K., Kubota T., Said J., Koike M., Binderup L., Uskokovic M., et al. Combination therapy of a vitamin D3 analog and all-trans-retinoic acid: effect on human breast cancer in nude mice. Anticancer Res. 1999, 19:519-524.
119. Sundaram S., Sea A., Feldman S., Strawbridge R., Hoopes P.J., Demidenko E., et al. The combination of a potent vitamin D(3) analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 2003, 9:2350-2356.
120. Ooi L.L., Zhou H., Kalak R., Zheng Y., Conigrave A.D., Seibel M.J., et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010, 70:1835-1844.
121. Ooi L.L., Zheng Y., Zhou H., Trivedi T., Conigrave A.D., Seibel M.J., et al. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone 2010, 47:795-803.
122. Zinser G., Packman K., Welsh J. Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 2002, 129:3067-3076.
123. Colston K.W., Berger U., Wilson P., Hadcocks L., Naeem I., Earl H.M., et al. Mammary gland 1,25-dihydroxyvitamin D3 receptor content during pregnancy and lactation. Mol. Cell Endocrinol. 1988, 60:15-22.
124. Zinser G.M., Welsh J.E. Accelerated mammary gland development during pregnancy and delayed post-lactational involution in vitamin D3 receptor null mice. Mol. Endocrinol. 2004, 18:2208-2223.
125. Mezzetti G., Barbiroli B., Oka T. 1,25-Dihydroxycholecalciferol receptor regulation in hormonally induced differentiation of mouse mammary gland in culture. Endocrinology 1987, 120:2488-2493.
126. Kemmis C.M., Salvador S.M., Smith K.M., Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J. Nutr. 2006, 136:887-892.
127. Welsh J., Wietzke J.A., Zinser G.M., Byrne B., Smith K., Narvaez C.J. Vitamin D-3 receptor as a target for breast cancer prevention. J. Nutr. 2003, 133:2425S-2433S.
128. Mezzetti G., Monti M.G., Casolo L.P., Piccinini G., Moruzzi M.S. 1,25-Dihydroxycholecalciferol-dependent calcium uptake by mouse mammary gland in culture. Endocrinology 1988, 122:389-394.
129. Bhattacharjee M., Wientroub S., Vonderhaar B.K. Milk protein synthesis by mammary glands of vitamin D-deficient mice. Endocrinology 1987, 121:865-874.
130. Peng X., Hawthorne M., Vaishnav A., St-Arnaud R., Mehta R.G. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 2009, 113:31-41.
131. Jacobson E.A., James K.A., Newmark H.L., Carroll K.K. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res. 1989, 49:6300-6303.
132. Zinser G.M., Suckow M., Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 2005, 97:153-164.
133. Zinser G.M., Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 2004, 25:2361-2372.
134. Anzano M.A., Smith J.M., Uskokovi M.R., Peer C.W., Mullen L.T., Letterio J.J., et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 1994, 54:1653-1656.
135. R.G. Mehta, E.A. Hussain, R.R. Mehta, T.K. Das Gupta, Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of vitamin D. Mutat Res 523-524 (2003) 253-264.
136. Mehta R.G., Moriarty R.M., Mehta R.R., Penmasta R., Lazzaro G., Constantinou A., et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J. Natl. Cancer Inst. 1997, 89:212-218.
137. Chen P., Hu P., Xie D., Qin Y., Wang F., Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 2010, 121:469-477.
138. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 2010, 128:1414-1424.
139. Yin L., Grandi N., Raum E., Haug U., Arndt V., Brenner H. Meta-analysis: Serum vitamin D and breast cancer risk. Eur. J. Cancer 2010, 1:188-191.
140. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am. J. Clin. Nutr. 2007, 85:1586-1591.
141. Chlebowski R.T., Johnson K.C., Kooperberg C., Pettinger M., Wactawski-Wende J., Rohan T., et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J. Natl. Cancer Inst. 2008, 100:1581-1591.
142. Neuhouser M.L., Sorensen B., Hollis B.W., Ambs A., Ulrich C.M., McTiernan A., et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am. J. Clin. Nutr. 2008, 88:133-139.
143. Goodwin P.J., Ennis M., Pritchard K.I., Koo J., Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 2009, 27:3757-3763.
144. Rainville C., Khan Y., Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J. 2009, 2:8390.
145. Khan Q.J., Reddy P.S., Kimler B.F., Sharma P., Baxa S.E., O'Dea A.P., et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res. Treat. 2010, 119:111-118.
146. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
147. Tang C., Chen N., Wu M., Yuan H., Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009, 117:391-399.
148. Whitfield G.K., Remus L.S., Jurutka P.W., Zitzer H., Oza A.K., Dang H.T., et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell Endocrinol. 2001, 177:145-159.
149. Egan J.B., Thompson P.A., Vitanov M.V., Bartik L., Jacobs E.T., Haussler M.R., et al. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. Mol. Carcinog. 2010, 49:337-352.